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ABSTRACT: N-Leucinyl benzenesulfonamides have been discovered as a novel class of potent inhibitors of E. coli leucyl-tRNA 
synthetase. The binding of inhibitors to the enzyme was measured by using ITC. This provided information on enthalpy and entropy 
contributions to binding, which, together with docking studies, were used for SAR analysis. Enzymatic assays revealed that N-leucinyl 
benzenesulfonamides display remarkable selectivity for E. coli leucyl-tRNA synthetase compared to S. aureus and human orthologs. 
The simplest analog of the series _ N-leucinyl benzenesulfonamide (R = H) showed the highest affinity against E. coli leucyl-tRNA 
synthetase and also exhibited antibacterial activity against gram-negative pathogens (the best MIC = 8 ug/mL, E. coli ATCC 25922) 
which renders it as a promising template for antibacterial drug discovery.
Aminoacyl-tRNA synthetase (aaRS) enzymes are conserved 
across bacteria and at the same time exhibit considerable evo-
lutionary divergence with respect to the human enzymes.  They 
have therefore attracted attention as therapeutic targets for the 
discovery of broad-spectrum antibacterials.1-4 The aaRS en-
zymes covalently link the cognate amino acid to its transfer 
RNA (tRNA) as part of protein biosynthesis. Aminoacylation 
of tRNA is a two-step process in which the enzymes initially 
form an aminoacyl adenylate intermediate from the amino acid 
and ATP. The amino acid is then transferred to the terminal 
adenosine residue of the tRNA. The enzymes are classified into 
two groups, depending upon whether the amino acid is trans-
ferred to the 2’- (Class I) or the 3’-hydroxyl group (Class II) of 
adenosine. Clinical validation of class I aaRS enzymes as drug-
gable targets has been provided by the isoleucyl-tRNA synthe-
tase (IleRS) inhibitor, mupirocin,5-7 also known as pseudomonic 
acid 1 (Figure 1), which is used to treat topical skin infections.8 
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Figure 1. Representative class I aaRS inhibitors 
 A boron-containing molecule 2 (AN3365, GSK2251052, Fig-
ure 1)9 that inhibits leucyltRNA synthetase (LeuRS) by binding 
at the enzyme’s editing site has also been evaluated clinically, 
although its development is encumbered due to the rapid emer-
gence of resistance.10,11 Nevertheless, to date, no catalytic site 
LeuRS inhibitor has been advanced to clinical investigation.  
Most of the precedent work to develop LeuRS catalytic site 
inhibitors has focused on non-hydrolyzable aminoacyl-AMP in-
termediate analogues such as LeuAMS 3 (Figure 1).12-14 Potent 
inhibitors have been discovered, but in general these com-
pounds lack selectivity for bacterial compared to human aaRSs 
and also lack antibacterial activity, the latter owing to poor in-
tracellular accumulation.13,14 
Selectivity issues of bacterial LeuRS inhibition were over-
come by researchers at Cubist who have developed acyl-
sulphonamide-based LeuRS inhibitors 4 (Figure 1) in which the 
adenine ring is replaced with a substituted thiazole.15 Moreover, 
selective inhibitors of the homologous IleRS enzyme, with ac-
tivity against Gram-positive organisms have been achieved by 
replacing the adenine ring with substituted phenyltetrazoles 
linked to the sugar ring by a short alkyl group.16  
A drawback of adenosine analogues is their relatively com-
plex structures. This limits rapid chemical modifications to ob-
tain crucial requirements such as selectivity and antibacterial 
activity. There are some examples in the recent literature show-
ing that the adenylate can be substituted with a benzenesulfon-
amide motif. Teng et al. have developed selective nanomolar 
benzenesulfonamide based inhibitors 5 (Figure 2) of bacterial 
ThrRS, including the enzyme from E. coli.17  In these inhibitors, 
the meta-substituent at the benzenesulfonamide (such as inda-
zole) was designed to pick up the H-bond interactions seen in 
the adenine of the native substrate. Zhang et al. have developed 
low micromolar benzenesulfonamide 6 (Figure 2) based T. 
brucei LeuRS inhibitors.18 According to modeling studies, the 
acyl-thiourea group in these inhibitors provides additional H-
bonding interactions with the enzyme. These findings moti-
vated us to explore N-leucinyl benzenesulfonamides 7 as sim-
plified bacterial LeuRS inhibitors (Table 1, see Supporting In-
formation for the synthesis). The affinity of the inhibitors 7 for 
Escherichia coli LeuRS was determined using ITC. Enzymatic 
inhibition of compounds 7 against E. coli, S. aureus and human 
LeuRS was also determined.19 
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Figure 2. Known benzenesulfonamide-based aaRS inhibitors  
Our initial hypothesis, guided by the known aaRS acylsulfon-
amide inhibitors and by analogy to inhibitor interactions at 
other ATP binding sites, for example in kinases, was that hy-
drogen bond interactions with Val569 and Met620, to mimic 
the interaction with adenine in the native substrate, would be 
beneficial.    Inhibitor design was performed by docking of the 
benzenesulfonamide derivatives into a protein model based on 
an X-ray structure of E. coli LeuRS. These studies suggested 
that this could be achieved via amino pyridine or amino pyrim-
idine substituents at the meta position of of the benzenesulfon-
amide (Figure 3, compound 7c shown as an example). Based on 
these considerations, several analogues 7a-c were prepared and 
were found to exhibit binding affinity at nanomolar concentra-
tions against E. coli LeuRS in ITC experiments. Notably, potent 
inhibition of E. coli LeuRS with high selectivity versus S. au-
reus and human LeuRS were also observed (Table 1, Entries 1-
3). Interestingly, the installation of a methyl group in the pyrim-
idine ring (compound 7c) led to an increased enthalpic contri-
bution compared to analogues 7a,b. However, this improve-
ment is accompanied by a balancing decrease in entropic con-
tribution to leave KD practically unaltered. Replacement of the 
methyl with a phenyl group (compound 7d, Table 1, entry 4) 
had a negative impact on binding due to reduced enthalpy com-
pared to compound 7c, which to some extent was counterbal-
anced with increased entropy. The net binding constant was un-
expectedly strong given that compound 7d does not fit into the 
crystallographically-observed structures of E. coli LeuRS. This 
suggests further (as yet unobserved) conformational changes in 
the LeuRS structure on ligand binding which will require crys-
tallography studies in the future to understand.  
Amino pyridine 7e (Table 1, entry 5) showed similar ITC re-
sults to amino pyrimidine 7c which indicates no contribution of 
pyrimidine N1 to the binding. On the other hand, analogue 7f 
(Table 1, entry 6) without amino group showed decreased en-
thalpy of binding compared to inhibitor 7c, indicating that 
amino group provides additional H-bonding. However, com-
pound 7f has comparable KD which is again due to counterbal-
ancing with decreased binding entropy for this compound.  
 
 
Figure 3.  Docked poses of 7c (purple), 7h (orange) and 7j 
(cyan) in active site of E. coli LeuRS (3zgz) 
 
The favourable decrease of binding entropy for compound 7f 
suggested the preparation and testing of more lipophilic com-
pounds 7g-i (Table 1, entries 7-9).  Pyridine and phenyl substi-
tuted analogues 7g,h showed  KD comparable to inhibitors 7a-
c,e,f.  However, by increasing the aromatic ring size to naphthyl 
(compound 7i), a considerable loss of binding enthalpy was ob-
served which indicated that this compound does not adopt the 
optimal conformation in the active site of the enzyme. 
 
 Table 1. ITC binding constants of N-leucinyl benzenesulfonamides 7 to E. coli LeuRS and the enzymatic potency against E. coli,  
S. aureus and human LeuRS. 
R
S
O O
N
H
O
NH2
7  
Entry R,  compound number 
E.coli LeuRS 
ITC,a KD, nM 
ITC,a ΔH, 
kcal·mol-1 
ITC,a -TΔS, 
kcal·mol-1 
E.coli LeuRS 
IC50, nMb 
S. aureus LeuRS 
IC50, nMb 
Human LeuRS 
IC50, nMb 
1 
N
NH2N
7a 
14.5±0.3 -9.5±0.5 -1.2±0.5 54 9.2 x 103  3.9 x 103  
2 
N
H2N
7b 
12.8±1.2 -9.0±0.3 -1.7±0.3 14 650  490 
3 
N
NH2N
Me
7c 
10±3 -12.5±1.2 1.6±1.0 41 4.4 x 103  160 
4 
N
NH2N
Ph
7d 
56±17 -7.6±0.3 -2.3±0.4 224 3.6 x 103 33 
5 NH2N
7e 
13.9±1.9 -9.10±0.11 -1.62±0.07 23 1.7 x 103  850 
6 
N
N
Me
 
7f 
22±4 -7.05±0.05 -3.40±0.13 47 2.7 x 103  2.0 x 103  
7 
N
 
7g 
10.9±1.5 -8.27±0.11 -2.6±0.18 13 920  1.2 x 103  
8 
 
7h 
10.2±1.4 -8.1±0.5 -2.8±0.5 32 640  3.4 x 103  
9  
7i 
64±18 -6.5±0.9 -3.3±0.8 65 1.0 x 103  220 
10  
7j 
1.3±0.14 -13.1±0.3 1.1±0.2 35 5.4 x 103  1.1 x 103  
aITC data for binding to  E. Coli LeuRS enzyme, bIC50 were within 10% of the error range. 
 
  
 At this point, our interpretation of the data indicated a limited 
contribution to KD from polar interactions and a variable contri-
bution from more lipophilic compounds.  Therefore, we decided 
to simplify the scaffold further. The simplest member of N-leu-
cinyl benzenesulfonamide class, inhibitor 7j was prepared and 
it was found to exhibit the best binding affinity against E. coli 
LeuRS with a KD of 1.4 nM. The ITC data imply that binding 
of compound 7j with LeuRS is enthalpy driven and that entropy 
does not provide a favorable contribution to the Gibbs free en-
ergy of binding. 
Antibacterial susceptibility testing against a standard labora-
tory strain of E. coli (BW25113) was performed for all inhibi-
tors 7a-j. Only inhibitor 7j showed detectable activity (Table 2, 
entry 1) and was screened against wider panel of strains. The 
best antibacterial activity was observed against E. coli (ATCC 
25922) strains while it was weaker for other gram-negative 
pathogens such as K. pneumoniae, P. aeruginosa and E. cloa-
cae. No activity was detected against S. aureus as a representa-
tive Gram-positive pathogen. For comparison, compound 7c 
was also tested against the strains listed in Table 2, however it 
showed no detectable activity against any of the strains. 
Table 2. Activity of inhibitor 7j against a panel of selected 
bacterial strains 
Strains Name 7j 
MIC ug/mL 
E. coli BW25113 32 
E. coli ATCC 25922 8 
K. pneumoniae clinical isolate 64 
P. aeruginosa PA01 64 
Acinetobacter spp ATCC 19606 64 
E. cloacae clinical isolate 128 
S. aureus JE2 >256 
 
Antibacterial activity of compounds 7c and 7j was tested 
against derivatives of E. coli (BW25113) lacking key compo-
nents of multidrug efflux transporter components TolC and 
AcrAB.20 Nevertheless, neither tolC deletion strain nor AcrA 
and AcrB deletion strains showed improved susceptibility to 
compounds 7c,j.  This indicates that the antibacterial activity of 
N-leucinyl benzenesulfonamides 7 is limited by additional 
mechanisms other than efflux.  
In summary, we have identified N-leucinylbenzene sulfona-
mides as a novel class of E. coli LeuRS inhibitors. The simplic-
ity and potency of this class offers significant potential for the 
development of much needed novel antibacterial agents. 
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